Can I stop taking Alpelisib at will?

Alpelisib (Alpelisib)-Piqray is a selective inhibitor targeting the PI3K pathway. It is often used in combination with Fulvestrant to treat patients with hormone receptor-positive, HER2-negative advanced breast cancer who carry PIK3CA mutations. It inhibits tumor growth and metabolism by blocking the signaling pathway of PI3Kα isoforms in tumor cells, thereby achieving disease control. Because this drug is a targeted sustained inhibitory drug, once you start taking it, it is usually not recommended for patients to stop taking it on their own.

The treatment principle of Piqray is different from traditional chemotherapy. It relies on long-term maintenance of molecular pathway inhibition to stabilize the disease. Once the drug is stopped suddenly, tumor cells may reactivate the PI3K signaling pathway, leading to accelerated disease progression or drug resistance rebound. Therefore, unless serious adverse reactions occur or the doctor believes that treatment must be discontinued, you should continue to take it as directed. If the patient wants to stop taking the drug due to side effects such as high blood sugar, rash, gastrointestinal discomfort, etc., it is recommended to communicate with the doctor first and adjust the plan by reducing the dose or temporarily stopping the drug, rather than stopping on your own.

In international clinical experience, apelvis is usually used in combination with fulvestrant, and the treatment course is continued on the principle that "the disease has not progressed or unacceptable toxicity has not occurred." Patients need to regularly monitor blood sugar, liver and kidney function, and weight changes during treatment to evaluate drug safety. If serious adverse reactions occur, the doctor will choose to temporarily stop the drug, reduce the dose, or permanently discontinue it according to the situation. It needs to be emphasized that blindly stopping the drug and then re-using it may lead to a decrease in efficacy or an increase in the risk of drug resistance.

In addition, Apelvis is an oral targeted drug with a long half-life. It takes time to clear the drug from the body after stopping the drug. If it is interrupted and resumed at will, fluctuations in blood concentration may increase the risk of adverse reactions. Therefore, patients who need to discontinue treatment should follow their physician's instructions to ensure a smooth transition and monitor tumor response.

Reference materials:https://www.piqray.com/